- Home
- CRWV vs TAK Comparison
CRWV vs TAK Comparison
Compare CRWV & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRWV
- TAK
- Stock Information
- Founded
- CRWV 2017
- TAK 1781
- Country
- CRWV United States
- TAK Japan
- Employees
- CRWV N/A
- TAK N/A
- Industry
- CRWV
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- CRWV
- TAK Health Care
- Exchange
- CRWV NYSE
- TAK Nasdaq
- Market Cap
- CRWV 41.6B
- TAK 45.8B
- IPO Year
- CRWV 2025
- TAK N/A
- Fundamental
- Price
- CRWV $165.20
- TAK $15.34
- Analyst Decision
- CRWV Buy
- TAK
- Analyst Count
- CRWV 15
- TAK 0
- Target Price
- CRWV $75.31
- TAK N/A
- AVG Volume (30 Days)
- CRWV 21.5M
- TAK 2.1M
- Earning Date
- CRWV 08-14-2025
- TAK 07-30-2025
- Dividend Yield
- CRWV N/A
- TAK 3.54%
- EPS Growth
- CRWV N/A
- TAK N/A
- EPS
- CRWV N/A
- TAK 0.45
- Revenue
- CRWV $2,708,374,000.00
- TAK $30,595,075,281.00
- Revenue This Year
- CRWV $144.33
- TAK $1.01
- Revenue Next Year
- CRWV $134.59
- TAK $1.04
- P/E Ratio
- CRWV N/A
- TAK $66.17
- Revenue Growth
- CRWV 17009.12
- TAK 7.45
- 52 Week Low
- CRWV $33.52
- TAK $12.80
- 52 Week High
- CRWV $187.00
- TAK $15.53
- Technical
- Relative Strength Index (RSI)
- CRWV N/A
- TAK 58.81
- Support Level
- CRWV N/A
- TAK $14.90
- Resistance Level
- CRWV N/A
- TAK $15.53
- Average True Range (ATR)
- CRWV 0.00
- TAK 0.14
- MACD
- CRWV 0.00
- TAK 0.03
- Stochastic Oscillator
- CRWV 0.00
- TAK 80.41
About CRWV COREWEAVE INC
CoreWeave Inc is a modern cloud infrastructure technology company that offers the CoreWeave Cloud Platform which consists of proprietary software and cloud services that deliver the automation and efficiency needed to manage complex AI infrastructure at scale. Its platform supports the development and use of ground-breaking models and the delivery of the next generation of AI applications that are changing the way of living and working across the globe.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.